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Abstract 
Advanced and metastatic cancer has a complex diagnostic and management profile that places a heavy long-term burden on 
patients and healthcare systems. Little attention has been given to patients’ experiences across their entire clinical journey. 
Using a qualitative, longitudinal methodology over a ten-month period, we examined the symptom-to-outcome trajectories of 
seven people attending a medical oncology clinic at a large, public tertiary referral center in Sydney, Australia. Rather than 
care being experienced as a largely linear progression through diagnosis, treatment and onto surveillance in which life may 
return to ‘normal’, participants are embedded in a cyclical clinical pathway. Recurrence or metastases are not a matter of ‘if’ 
but ‘when’. This model of the patient journey points to a need for longitudinal, person-centered services to support the 
growing population of people with melanoma. 
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Introduction 
 
A model of the clinical journey experienced by particular 
patient populations from symptom identification to 
outcome can help healthcare providers to plan appropriate 
and supportive care.1 There is a gap in qualitative research 
that examines and represents patients’ experiences of their 
clinical journeys. Our research seeks to address that gap. 
 
Most research on patient experience is cross-sectional, 
taking soundings of the care received at specific points in 
time and place. The few longitudinal studies of progressive 
patient experience in the context of cancer typically 
examine specific aspects of care, such as supportive care,2 
psychosocial needs,3 or more defined domains such as 
quality of life status4 and informational needs.5  
 
Our study aims to add value to this body of literature by 
understanding how a patient cohort experiences different 
phases in the overall clinical management of their disease. 
We investigated the healthcare experiences of people with 
advanced and metastatic melanoma. Melanoma is a cancer 
of the pigment cells of the skin. There is evidence that 
while the incidence of cancer overall is decreasing, cases of 
melanoma are increasing.6 In its rising prevalence, and also 
in light of the aggressive and recurrent nature of the 
disease, a multitude of services and healthcare settings are 
implicated in the pathways to treatment, follow-up and 
palliative care. Melanoma is increasingly being 
conceptualized as a chronic public healthcare problem.7-10 
 
Earlier work investigating over 200 web-based personal 
accounts written by people with melanoma established a 
meta-view of the healthcare journeys of people with 
varying stages of melanoma.11 The meta-view identified 
key phases of the personal patient journey in the 
progression of health care-events related to disease 
management. These phases were characterized by ill-
defined symptom identification, problematic diagnosis, 
disfiguring treatment, psychological issues related to 
lifestyle and sun exposure, longitudinal surveillance 
requirements and, for some patients, recurrence or 
metastases. We know from that study that the values and 
principles of patient-centered care, which are to support 
people in understanding and managing their own health, 
may not be consistently applied throughout key phases of 
the melanoma healthcare journey. 
 
Advanced and metastatic stages of melanoma, involving 
spread to distant lymph nodes or organs such as the lungs, 
liver, brain or bone, create a different kind of journey. 
Visible skin changes that clue people into the possible 
presence of early stage cutaneous melanoma are not 
necessarily present in metastatic melanoma. The spread to 
organs may not be detected until serious physical 
manifestations are present. Symptom detection, diagnostic 
pathways, treatment and follow-up care take place in a life-
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threatening context.12 In order to understand these 
patients better and provide targeted support and care, we 
need to comprehend and model their journeys. In this 
paper we investigate a potentially generalisable model of 
the patient journey for people with advanced or metastatic 
melanoma. 
 
Method 
 
Participants 
Our participants were drawn from a population of people 
attending medical oncology clinics at a public tertiary 
referral center in Sydney, Australia. Potential participants 
were being seen by an oncologist for the disease 
management of tumours suspected or confirmed to be 
melanomas.  
 
The inclusion criteria were patients who had a potential or 
confirmed diagnosis of advanced or metastatic malignant 
melanoma, over 18 years of age and English-speaking. The 
period of recruitment was six months, from November 
2015 to May 2016. Prospective participants were patients 
attending for the first time, or ongoing patients of the 
clinic. Although patients were cared for by multiple 
doctors, nurses, allied health staff and other specialists, all 
potential participants were patients of one medical 
oncologist.  
 
Recruitment 
Target participants were screened by the medical 
oncologist ahead of the scheduled clinic visit. Where 
eligible, the oncologist would briefly describe the study 
and ask the patients if they were interested in meeting with 
the field researcher. If the patient agreed, the researcher 
met the patient separately, describing the study and 
seeking informed consent. Nine (9) participants agreed to 
join the study and to the publication of de-identified study 
findings. Two participants died before they could take part 
in the initial interviews. The others participated in an initial 
interview of at least 20 minutes in length. Enrolees agreed 
to be shadowed by the field researcher during clinical 
consultations and treatments, and to ongoing interviews 
either in person in a setting of their choice or by phone. 
 
The study ensued over the ten-month period from 
November 2015 to September 2016, dictated by the 
personal and health needs of the participants and the 
logistics of doing in-depth social research of this kind. One 
participant was found after some weeks into the study to 
have been misdiagnosed; what was thought initially to be a 
malignant melanoma on the back of his eye was found not 
to be. Data collected on that participant to the point of 
diagnosis have been included because his perspective 
throughout was that he had a melanoma recurrence, and 
his experiences were thus from the point of view of 
someone with melanoma.  
 
Participants’ characteristics 
Table 1 presents the key demographic characteristics of 
the seven study participants and the status of their health 
at diagnosis. 
 
 
Table 1. Participants’ demographic profiles and health histories 
 
Participant Gender Age* Stage1 Melanoma/ 
tumour  
Length of time 
since previous 
melanoma 
How latest diagnosis occurred 
PA F 75+ 4 lungs, stomach, 
skull & brain 
20 years After weeks of becoming forgetful 
and confused, PA suffered stroke-
like symptoms and was taken to 
hospital where investigations led to 
the identification of tumours  
PB M 75+ 4 left leg lymph 
nodes, 
lung 
12 years Ultrasound for deep vein 
thrombosis (DVTs) identified 
enlarged lymph glands 
PC M 25+ 3-4 right arm lymph 
nodes 
2 months Enlarged lymph nodes were 
identified in first surveillance scan 
after melanoma on back had been 
excised  
PD F 65+ 4 stomach, lung, 
liver 
4.5 years Fell at home, taken to hospital, 
investigations led to the 
identification of tumours 
PE M 85+ 1/4 eye N/A Scheduled cataract examination 
identified lump 
PF M 70+ 4 rib, spine, kidney  2 years Investigation of ongoing pain from 
broken rib led to the identification 
of tumours 
PG M 70+ 4 lung, pancreas 4 years Investigation of abdominal pain led 
to the identification of tumours 
 
Patients’ experiences of metastatic melanoma framed in a dynamic narrative, Lamprell et al. 
  
 
 
Patient Experience Journal, Volume 6, Issue 1 – 2019 89 
Data collection 
We employed the methodology of interpretive description 
to collect and analyse our data.13 Interpretive description 
takes a social constructivist and naturalistic approach. The 
methodology emerged from social science and has been 
applied most often in nursing research and is intended to 
generate knowledge that can be translated into practice 
and policy.14 Interpretive description is a “second-
generation” qualitative approach:15 it promotes a 
multidisciplinary research agenda in investigating 
“complex experiential clinical/practical phenomena”,16 
drawing on methodological principles of grounded theory, 
ethnography and phenomenology. 
 
Data comprised transcripts of interviews with participants, 
observational field notes and medical information 
contributed by the supervising oncologist. This 
triangulated data collection helped form meta-views of 
what happened as participants pursued their longitudinal 
goal of resolving the threats to their lives. Further details 
on methods are provided elsewhere.17 
 
Interviews were semi-structured, supported by an 
interview guide, encouraging an open dialogue and 
allowing participants to move between ‘question and 
answer’ mode and ‘story-telling’ mode with the aid of 
prompt questions. A key prompt word ‘journey’ was used 
to communicate that the study was interested in the past, 
present and imagined future of participants’ healthcare 
experiences.  
 
Analysis 
Data were downloaded into the software package 
NVivo10 (QSR International). The analytic procedures in 
interpretive description methodology “capitalize on such 
processes as synthesizing, theorizing and recontextualizing 
rather than simply sorting and coding”.18 We coded textual 
data into themes and iteratively coded the elements and 
properties of participants’ descriptions and reflections, 
classifying them into interpretable categories, mapped 
progressively into a study framework.  
 
Results 
 
The analysis created a meta-view (see Figure 1); an 
aggregated narrative of the healthcare journeys of 
participants structured into four pivotal shifts in patient 
experience: Initiation; Identification; Action; and 
Adaption. A significant feature of this meta-view is its 
circular dynamic pointing to profound and unending 
dependence on the healthcare system. This contrasts with 
the ideal experience of healthcare services as a 
fundamentally linear journey from diagnosis to cure or 
stability of disease. In this section we report the shifting 
phases of experiences that define this circular meta-view.  
 
1. Initiation: Seeking medical help 
Six of the seven participants had been treated for a 
primary melanoma in the past. They had completed their 
long-term surveillance programs and believed they were 
clear of disease. The reasons they were seeking medical 
care this time did not relate to melanoma. They were 
seeking care for: suspected hernia in the groin (PB); 
confusion and forgetfulness (PA); concern about deep 
vein thrombosis (DVT) (PB); a fall down a flight of stairs 
(PD); detection of a lump on the eye during a cataract 
examination (PE); increasing pain from a fractured rib 
(PF) and; stomach pain (PG). The final participant (PC) 
was still in the care pathway for a primary melanoma when 
enlarged lymph nodes were diagnosed. 
 
Decisions about seeking care 
Personal values and beliefs about health management 
feature strongly. Some participants, such as PB and PG, 
were quick to seek medical care for health concerns. Given 
 
Figure 1. A meta-view of the clinical trajectory experienced by people with advanced and metastatic melanoma 
        
                            
 
 
Initiation: Seeking medical 
help to resolve heath concerns
Identification: Complex 
investigations leading to 
diagnosis
Action: Treatment, 
palliation and threat of 
death
Adaption: Tumour 
surveillance, ongoing 
treatment and side effects
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a history of DVT and a discomfort in his left groin prior 
to an upcoming flight, PB organized a pre-emptive 
ultrasound. PG had decided that a recent episode of 
sudden and severe stomach pain, though resolved and not 
ongoing, was worthy of further investigation.  
 
Other participants delayed seeking healthcare. PA believed 
that her ongoing bouts of confusion and forgetfulness 
indicated stress brought on by current circumstances in 
her life. She rationalized that the stress was a temporary 
condition and there was no reason to seek medical advice. 
PB had been told by a clinician to expect ongoing pain 
from a fractured rib; though the pain was intensifying, he 
valued himself as a stoic person and rationalized that since 
he had an upcoming appointment with a specialist for 
another health condition, he could wait until then to seek 
advice. PC described scratching an area on his back for six 
months before seeing his doctor because he was 
distracted, dealing with complex personal issues.   
 
2. Identification: Complex investigations leading to 
diagnosis  
This phase was characterized by multiple investigations of 
possible diagnoses, eventually concluding that a previous 
melanoma had recurred, advanced or metastasized. 
Further investigations were often required, including 
proto-oncogene B-Raf (BRAF) gene mutation testing.  
 
Physical and psychosocial impact of investigations and consultations 
Participants noted complex and sometimes confusing 
pathways to diagnosis, involving logistical challenges, 
substantial time commitments and, for some, pain. PE 
observed that scans and consultations were scheduled “one 
thing at a time” in contrast to being co-ordinated into 
sequential events in the one location or on the one day. He 
found it tiring to keep up his commitments in other areas 
of his life. PF described his pain as shifting from a “three” 
to a “ten” when moving from lying to sitting to standing 
during physical examinations. He found that getting in and 
out of the car to come to the hospital was very difficult 
and distressing for him and his wife. For PG, an open lung 
biopsy caused fresh problems: “Until last week when they took 
a section of lung for a BRAF test no-one would have known I had a 
serious illness. I felt good and looked fine. Now I’m in pain from the 
wound and the nerve damage.”  
 
Information pathways and knowledge absorption 
Though participants showed interest when clinicians and 
technicians explained scanning equipment and the 
meaning of visually represented results, most found it 
challenging to understand and absorb the information. Six 
of the seven participants interchangeably referred to CTs 
(Computed Tomography), MRIs (Magnetic Resonance 
Imaging) and PET (Positron Emission Tomography) 
scans, or referred to them generically as ‘scans’. PB 
expressed personal concern, and concern for others, about 
the difficulties of staying focused during consultations: 
“Because you're the person with the problem, you won't actually hear 
what the doctor is actually saying. Your partner has got to be primed 
up … ask them to listen for you because you won't be able to listen.”  
 
Most participants did not do background reading beyond 
the information provided by hospital and individual 
clinicians: “I'm an absolute outsider as far as medical things are 
concerned even though I’ve been through all this before. I'm not like 
some friends who search, trawl the Internet to get information. I don't 
do that.” (PG). Some were concerned with the negative 
implications of ‘knowing too much’: “To tell you the truth, 
they said to read up about it on the internet but it's scary stuff when 
you start reading and … being negative just feeds it, got to be positive 
in it.” (PC) 
 
Impacts of diagnosis  
Four of the seven participants (PB, PD, PE, and PG) 
appreciated the final diagnoses of metastasized melanoma 
as a result of coincidence and luck. PD, for example, 
noted: “If I hadn't have fallen down the stairs and been taken to 
hospital and had the scan, I wouldn't have known I had it… I've 
just been really lucky.”  
 
Participants also expressed a range of emotions, from 
devastation through to resignation, that “the beast was back”. 
PD described her “shock” that she had been given the “all 
clear” and yet had been diagnosed again: “Every time I have 
one removed, you think there's going to be no more, this is my last 
and low and behold, I've got more. So, it's just pretty invasive.” PB 
commented that he had been expecting a recurrence: “I 
was essentially cleared. But I always had the view in my subconscious 
that … it could come back.”  
 
Relational aspects of care during investigation and diagnosis 
Participants’ relationships and communication with 
clinicians and with healthcare providers was a prominent 
aspect of the Identification phase of the journey. PA 
deified her oncologist:  “As far as I’m concerned, you’re god. 
Whatever you say to do, I’ll do.” PE expressed a sense of great 
fortune in having both an oncologist and ophthalmologist 
as allies: “I'm just so lucky. Heavens above, to have these two 
specialists … Honestly, I nearly cry sometimes. They're so good and 
do everything for you.” PF wanted to know his life expectancy 
but excused his oncologist from having to make an 
accurate prediction: “I know it's impossible to answer, but how 
long have I got? ... Just a rough ball park, that's all I want to 
know.” PD empathized with the oncology nurses who had 
to navigate her collapsed veins: “I feel sorry for them taking 
blood … they don’t like having to do it. Causing me pain. I try to 
make it easy on them. ‘Don’t worry’, that sort of thing.” PG was 
more critical and struggled with the impact of 
communication gaps between practitioners: “They're not in 
touch with each other and you sort of feel … a link in the chain is 
broken, and so again it's that feeling of powerlessness.” 
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3. Action: Treatment, palliation, threat of death 
The third segment featured sets of events that filtered out 
ambiguities and narrowed down treatment options. During 
this segment, two participants died (PA and PF), which 
highlighted the time-critical nature of events in melanoma. 
Treatment options included systemic treatment—
medications injected or ingested to shrink or control the 
tumours—and locoregional treatment such as radiotherapy 
directed towards a specific problem area such as the brain 
or bones. Other options focused on palliative care, aiming 
to minimize the symptoms from the tumours. Our 
findings identified four key sets of experiences within this 
segment. 
 
Treatment decisions 
Most participants assumed they would take some kind of 
therapeutic action. “Both mum and dad were clear about the fact 
that we should do all we can.” (family of PA). PF chose not to 
be involved in decision-making, saying to the oncologist: 
“You make all the decisions for me and I go along with whatever you 
say.” PG described his approach as being one of choosing 
quality care and then following the directions of those with 
expertise. The option of seeking second opinions on 
treatment decisions was raised by two participants. PB 
noted: “People … probably don't necessarily realise that they have a 
choice.” PG described his oncologist as being very open to a 
second opinion: “He told me what he would be planning to do but 
also urged me to make contact with Q [oncologist at another 
treatment facility] and he wrote a referral.” 
 
Response to BRAF testing 
The wait time of up to four weeks for BRAF test results, 
which decide whether a particular type of systemic 
treatment would work, was a cause of concern for 
participants because it delayed treatment decisions. 
Participants described being “annoyed” by the wait and 
described the waiting period as “suspended animation” and 
“limbo”. 
 
Though participants commented that BRAF testing had 
been explained well to them, few made reference to the 
term ‘BRAF’ in their descriptions of their circumstances, 
instead referring to ‘the test’ or adopting an analogy used 
by the oncologist: “We're struggling to find out what the on and 
off switch is” (family of PA). Participants equated positive 
BRAF results with a treatment consisting of a course of 
tablets, whereas they equated immuno-therapy with a 
treatment involving a course of injections or “chemo” 
therapy. PD commented:  “It was either tablets or injections and 
he [oncologist] did a test and he's decided the injections were a better 
way to go for this.”  
 
Physical and psychosocial experiences of treatment 
All participants expected to experience difficulties in 
receiving treatment. Most described being well prepared 
for immune-therapy treatment and its potential side effects 
through information pamphlets and tours of treatment 
facilities. Hair loss after radiation to the tumour on her 
skull was described by PA as being of minimal concern. 
PD was satisfied that the “lumps” and “red marks” on her 
arms and legs were “routine for the treatment.” Two 
participants described uncertainty about the side effects 
they were experiencing. PG was not sure whether his 
itchiness was a side effect of treatment or a heat rash, but 
decided against informing his oncologist because the 
symptoms were controllable and quickly dissipated, and 
because he did not want treatment to stop. PB, on a 
clinical trial for Dabrafenib (a drug improving progression-
free survival of patients with advanced melanoma with 
mutations in the BRAF gene), was uncertain about the 
permanence of almost immediate side effects that included 
curly hair, body aches, fatigue and additional layers of skin 
on his feet that had to be “shaved off” every six weeks. He 
rationalized concern about these effects against the fact 
that his tumours were shrinking significantly. 
 
PB described the time commitment of his clinical trial as 
“significant”, comprising attendance at the hospital research 
unit every three to four weeks for a period of over five 
years, with a subsequent trial requiring him to travel to the 
hospital occasionally and be in contact by phone. He 
noted that he would have “lost sight of the objective” if not for 
the support of friends and family.  
 
Relational aspects of care during treatment 
In the Action phase all participants conveyed a heavy 
reliance on their oncologist. PA expressed to her 
oncologist the personal importance of his treatment plan: 
“You’ve no idea how much hope you’ve given me, and all my family, 
because they’ve all just dropped their bundles …”  PD identified 
her oncologist’s reputation as a basis for trust in her 
treatment: “He's got a good success rate apparently so there's every 
chance that it's going to go [right].” PF gave his oncologist 
discretionary power over his treatment and relieved him of 
the burden of treatment failure: “I have every confidence in 
yourself … If it works out good, if it works out bad, it doesn't 
matter, because I know you're doing your best.” 
 
On the other hand, PG expressed concern that 
information about his health status had not been well 
curated and communicated: “After the last scans [following a 
first round of Keytruda, an immunotherapy drug], I found out I have 
tumours I was never told about …. I was told I had them all the 
way along. Maybe they didn’t see those tumours as relevant ... I 
assumed they had told me everything.” 
 
4. Adaption: Tumour surveillance and treatment side 
effects  
Of the four participants who progressed into definitive 
treatment, two transitioned out of the treatment phase and 
were adapting to their ‘new normal’ by the close of the 
study. Their descriptions and reflections on key care 
experiences at this point comprise the following issues. 
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Health management related to surgery and medication 
As a result of extensive surgery to remove all lymph nodes 
in the left leg as far as the vena cavae, PB developed 
significant lymphedema. Each night and on vacation he 
pumped fluid from his leg, and every six to eight weeks he 
visited a lymphoedema physiotherapist to ensure his leg 
was being well managed. Side effects from the drug 
Dabrafenib received while on clinical trial continued to 
affect PB, though the addition of a second drug, 
Trametinib (a drug with a different mechanism that helps 
prolong the benefits of Dabrafenib) had largely rectified 
the side effects of the first drug. He rationalized the 
impact of side effects as a “small price to pay” for the 
survival longevity the trial drugs had provided him: “My 
feet are still a bit sore, some joints become inflamed—my eyesight is 
not as good as it was, by a long shot. But I am still alive after seven 
years on Dabrafenib and now in combo with Trametinib drugs!” 
 
Tumour surveillance and dependence on healthcare services for life 
decisions  
PB had scans every six months “and then I have a phone call 
from X [oncologist] and I find out whether I am going to live or die. 
I refuse to be down about it. You can’t look inward and feel sorry for 
yourself, it will serve no purpose.” 
 
At a follow-up consultation a year after surgery to remove 
most of the lymph nodes in his right arm, PC sought a 
second opinion regarding the completion of a tattoo on 
that arm: “I just got one half done and I wanted to get it finished 
… He said I can't get it done because I've had my glands removed. 
Is that correct?” 
 
Discussion 
 
The aim of this research was the exploration, description 
and thematic interpretation of seven unique sets of 
encounters with health care provision in the context of 
advanced and metastatic melanoma. While entry into the 
system and the journey along pathways of care from 
patients’ perspectives are markedly non-routine, our 
thematic analysis of the data identified four key transitional 
segments in the commonality of experiences.  
In this four-segment trajectory model, the second and 
third segments represent the critical periods of 
participants’ healthcare trajectories, based on rich data 
which contrast with the ‘bookends’ of the first and fourth 
segments. The four-phase model encompasses phases of 
Initiation, Identification, Action and Adaption and reflects 
the experience of advancement, recurrence or metastases 
of the disease and the high likelihood of further 
recurrence. This is differentiated from a model which 
suggest that populations of people go through a largely 
linear progression of disease management resulting in cure 
or disease stasis.  
 
The first segment, Initiation, draws attention to the non 
skin-related issues that drive people with advanced and 
metastatic melanoma to seek healthcare. It points to a 
need for information and education about metastases from 
melanoma.  
 
The second segment, Identification, highlights the 
complexity of diagnostic pathways related to metastatic 
melanoma. It features needs for individualized compassion 
and responsiveness in the delivery of medical care, 
underlined by participants’ concern with the physical and 
logistical demands of appointments and consultations. 
This stage is also characterized by participants’ perceptions 
of doctors as allies, mentors and oracles in the decision-
making process.  
 
The personal impact of timeliness features in the third, 
Action, segment. The wait times for BRAF test results 
contrasted with participants’ perceived urgency in forming 
decisive pathways for the management of the disease, 
creating a ‘hurry up and wait’ dynamic in their trajectory of 
care. Diagnosis occurring after surveillance programs had 
been completed—sometimes just weeks after participants 
had been given the ‘all clear’—points to a possible need 
for extended periods of intensive surveillance.  
 
The final segment, Adaption, reflects the distinctly circular 
nature of the care pathway for this patient population. For 
the two surviving participants, life is forever characterised 
by the reliance on healthcare services to treat remaining 
tumours, diagnose new tumours and manage the side 
effects of past and present therapies. Some patient-focused 
domains emerged as relevant: the need for personalized 
care for ongoing pain, lack of mobility and lymphedema as 
a result of the consequences of surgery and chemical 
treatment; and compassion from healthcare professionals 
in relation to the ongoing threat to life imposed by a lack 
of cure for metastatic melanoma. 
 
Limitations 
We believe this to be the first study to locate patients’ 
experiences of recurrent, advanced and metastatic 
melanoma as a meta-view of the clinical trajectory. One 
limitation is the small size of the participant group, 
although paradoxically this allows for the fashioning of a 
richer descriptive account. A small cohort makes detailed 
experiential data available for inspection and facilitates 
understanding of care from multiple vantage points. 
Correspondingly, it limits the extent to which the data is 
representative of others. 
 
Data of this type is not standardised, but adaptive to each 
participant’s state of health, living situation and availability. 
Given the health situations of the individual participants, 
we did not study other aspects of the participants’ lives, 
including any comorbidities. 
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Conclusion 
 
This study contributes a model of this patient population’s 
shifting responses to clinical journeys with advanced or 
metastatic melanoma. The model features a cyclical 
dynamic that is distinguishable from the ideal linear 
progression through diagnosis, treatment and onto long-
term surveillance. People with advanced and metastatic 
melanoma must adapt to the side-effects and collateral 
damage of initial and ongoing treatment and live with the 
perspective that renewed healthcare concerns are not a 
matter of ‘if’ but ‘when’.  
 
Our participants perceived the clinicians they interacted 
with, and particularly their oncologist, not only as medical 
experts but also as co-curators of their lives. Clinicians’ 
choices influenced the quality of their survivorship, down 
to such details as whether or not they can complete an 
unfinished tattoo.  
 
Our findings offer to various stakeholder groups in health 
care an understanding of the need for longitudinal person-
centered services to support this growing patient 
population. The typology may have merit beyond our 
patients and may encapsulate other clinical trajectories in a 
range of chronically life-threatening diseases.  
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